Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
USD bond activity | SUNAC China SUNAC 6.25 09/30/30 price increased by 1.42% to 15.497.
20/12/2025
The SUNAC 6.25 09/30/30 issued by Sunac China on December 20th is currently priced at 15.497, with an increase of +1.420%. The yield is --%.
Latest
2 m ago
President Trump and nine major pharmaceutical companies announced on Friday that they have reached an agreement to significantly reduce the prices of their drugs in government healthcare programs and for patients paying in cash. Pfizer, Gilead Sciences, Merck, and Roche's American subsidiary Genentech have all reached agreements. Novartis, Amgen, Bristol-Myers Squibb, Sanofi, and GlaxoSmithKline have also joined. Under the agreement, pharmaceutical companies will lower the prices of most drugs sold to low-income patients in healthcare programs and promise "significant savings" on widely used medications. Trump has been pressuring pharmaceutical companies to lower drug prices to the levels paid by patients in other countries. In July, Trump wrote a letter to the leaders of 17 major pharmaceutical companies urging them to provide "most favored nation" prices to healthcare programs and ensure that new drugs are not priced higher in the U.S. than in other wealthy countries. Five companies have already reached agreements with the government to control drug prices, while the remaining three companies that have not yet announced agreements are Regeneron, Johnson & Johnson, and AbbVie.
2 m ago
Merck: Reaches agreement with the US Department of Commerce to delay tariffs for three years. Merck aims to expand drug access channels and lower drug costs for American people, with Januvia, Janumet, and Janumet XR being supplied to eligible US patients at a cash price approximately 30% off the current list price. The company also pledges to invest over $70 billion in the United States.
5 m ago
Federal Reserve Governor Mester: The labor market is developing in a direction that we should stop.
7 m ago
Federal Reserve Governor Milan: The Federal Reserve has not yet started a new round of quantitative easing.
7 m ago
Federal Reserve Governor Milan: Easing policies is crucial to help the labor market.
See all latest